{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:03:41Z","timestamp":1780329821759,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022815","name":"Beijing Tongren Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.msard.2026.107204","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:44:11Z","timestamp":1776120251000},"page":"107204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antinuclear antibody and delayed immunotherapy predict disease evolution in isolated optic neuritis-onset NMOSD: A long-term cohort study"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8262-8744","authenticated-orcid":false,"given":"Liang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107204_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/acn3.52268","article-title":"The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population","volume":"12","author":"Carlson","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107204_bib0002","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70049","article-title":"Is a Benign Disease Course Possible in Untreated AQP4-IgG NMOSD?","volume":"32","author":"Siriratnam","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"10206","key":"10.1016\/j.msard.2026.107204_bib0003","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.msard.2026.107204_bib0004","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2026.107204_bib0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107204_bib0006","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaneurol.2024.4400","article-title":"Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder","volume":"82","author":"Kim","year":"2025","journal-title":"JAMa Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107204_bib0007","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3109\/s10165-011-0572-y","article-title":"Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases","volume":"22","author":"Katsumata","year":"2012","journal-title":"Mod. Rheumatol."},{"issue":"5","key":"10.1016\/j.msard.2026.107204_bib0008","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458511424590","article-title":"Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107204_bib0009","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1212\/NXI.0000000000000640","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","volume":"7","author":"Akaishi","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107204_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106340","article-title":"Rheumatic antibodies may serve as indicators of disease severity, relapse frequency, and ocular involvement in NMOSD patients","volume":"97","author":"Wang","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107204_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1865","article-title":"Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Fan","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.msard.2026.107204_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578151","article-title":"Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder","volume":"382","author":"Wang","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.msard.2026.107204_bib0013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00415-025-13180-3","article-title":"The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD","volume":"272","author":"Samadzadeh","year":"2025","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107204_bib0014","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1212\/NXI.0000000000000727","article-title":"Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD","volume":"7","author":"Jitprapaikulsan","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2026.107204_bib0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00415-025-13137-6","article-title":"Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder","volume":"272","author":"Wang","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107204_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.746959","article-title":"Serum Aquaporin 4-Immunoglobulin G Titer and Neuromyelitis Optica Spectrum Disorder Activity and Severity: A Systematic Review and Meta-Analysis","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107204_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104730","article-title":"Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients","volume":"75","author":"Lana-Peixoto","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107204_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106209","article-title":"Relapse risk factors analysis within 1 year after the first onset of neuromyelitis optica spectrum disorders: a two-center retrospective study","volume":"93","author":"Li","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107204_bib0019","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/acn3.70095","article-title":"Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: a cohort study","volume":"12","author":"Marrodan","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:25:32Z","timestamp":1780327532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"alternative-id":["S2211034826002403"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107204","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antinuclear antibody and delayed immunotherapy predict disease evolution in isolated optic neuritis-onset NMOSD: A long-term cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107204"}}